How does NUGX's PB Ratio compare to its peers?

Insufficient data to calculate NUGX's Price-To-Book Ratio vs. peers for valuation analysis.

How does NUGX's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

Insufficient data to calculate NUGX's Price-To-Book Ratio vs. industry for valuation analysis.

What is NUGX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate NUGX's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of NUGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate NUGX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

NuGenerex Immuno-Oncology (OTCPK:NUGX) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NUGX Stock Overview

NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. More details

NUGX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Shares are highly illiquid

Does not have a meaningful market cap ($10K)

NuGenerex Immuno-Oncology, Inc. Competitors

Goodbody Health

OTCPK:GDBY.F

US$36.0

Greenrose Holding

OTCPK:GNRS

US$1.8k

Sunwin Stevia International

OTCPK:SUWN

US$20.0k

Item 9 Labs

OTCPK:INLB

US$701.0

Price History & Performance

Summary of all time highs, changes and price drops for NuGenerex Immuno-Oncology
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.30
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	9,900.00%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	NUGX	US Pharmaceuticals	US Market
7D	0%	2.6%	0.5%
1Y	9,900.0%	13.1%	30.7%

Return vs Industry: NUGX exceeded the US Pharmaceuticals industry which returned -1.7% over the past year.

Return vs Market: NUGX exceeded the US Market which returned 4% over the past year.

Price Volatility

Is NUGX's price volatile compared to industry and market?
NUGX volatility
NUGX Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: NUGX's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine NUGX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	n/a	Joe Moscato	www.generex.com/nugenerex-family-of-companies

NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer.

NuGenerex Immuno-Oncology, Inc. Fundamentals Summary

How do NuGenerex Immuno-Oncology's earnings and revenue compare to its market cap?
NUGX fundamental statistics
Market cap	US$10.12k
Earnings (TTM)	-US$6.29m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is NUGX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NUGX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$6.29m
Earnings	-US$6.29m

Last Reported Earnings

Apr 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did NUGX perform over the long term?

See historical performance and comparison